CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Mechanism of Action
CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Dosage Overview
Dose Range
1 mg – 2 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
8–12 weeks
Reconstitution
Typical Dosage (Research)
CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Considerations for Men & Women
Women: Similar GH sensitivity considerations as sermorelin — women may respond at lower doses. The DAC (Drug Affinity Complex) version provides extended half-life, which may lead to more sustained GH elevation in women who already have higher baseline pulse amplitude.
Men: Standard dosing protocols. Often combined with a GHRP (like Ipamorelin) for synergistic GH release. Testosterone status can influence response magnitude.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Concentration: 2.5 mg/ml
Volume to inject: 0.40 ml
Syringe units (U-100): 40.0 units
Pre-filled with CJC-1295 defaults. Adjust values as needed.
Side Effects & Risks
Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
May affect blood glucose levels. Long-term effects on pituitary function not fully understood.
Who Uses CJC-1295
Those seeking anti-aging benefits, improved body composition, enhanced recovery, and better sleep.
Frequently Asked Questions
Similar Peptides
View All Alternatives →Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.